OR WAIT null SECS
June 29, 2020
The company has provided updates on its COVID-19 tests under development with Adeptrix and Cytiva, respectively.
June 25, 2020
The importance of capability and capacity of a CDMO partner to deliver drug substance and product testing should never be underestimated, considering the increasing complexity of compounds in development.
June 03, 2020
Recent drug recalls in the United States from nitrosamine contamination prompt the need for more sensitive impurity testing methods and a re-evaluation of acceptable lower limit levels.
June 02, 2020
Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.
May 05, 2020
The extension of the company’s product offerings to include the anti-certolizumab pegol antibodies offers critical reagents for the development of assays for TNF alpha inhibitor biologics and their biosimilars.
April 30, 2020
A comprehensive turnkey system based on LabVantage’s laboratory information management system platform allows laboratories to implement COVID-19 biobanking, testing, and research.
April 07, 2020
Characterizing and controlling protein aggregation is vital to ensure safety and efficacy of a biopharmaceutical product. In this interview, important aspects of protein aggregation and the tools available to address this issue are discussed.
April 02, 2020
Because conventional cleaning methods can risk product loss, biopharmaceutical manufacturers are often reluctant to use PDE/ADE limits to validate cleaning processes.
March 06, 2020
The acquisition will expand Nexelis’ immunology testing expertise.
March 02, 2020
Metrology has the potential to not only prevent harm to patients but also to support innovative therapeutic options.